Dalpiciclib in Combination With Exemestane and Trastuzumab Plus Pyrotinib in Early Triple Positive Breast Cancer

NCT04997798 · clinicaltrials.gov ↗

PHASE2

Phase

UNKNOWN

Status

30

Enrollment

OTHER

Sponsor class

Conditions

Breast Cancer
Estrogen Receptor Positive Tumor
HER2-positive Breast Cancer

Interventions

DRUG: Trastuzumab Pyrotinib Exemestane Dalpiciclib

Sponsor

First Affiliated Hospital of Zhejiang University